Samuel Frank, MD
Neurology · Boston, MANPI 1780646349
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $36,997 of the $48,015 with a category attached, or 77.1%. It is spread thinly across 15 manufacturers, the largest accounting for just 20.3%. 2025 is the largest year on record at $21,588, 4.8 times the $4,461 reported in 2019. Among neurology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $842.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$10K
- Teva Pharmaceuticals USA, Inc.$9K
- F. Hoffmann-la Roche AG$7K
- Sanofi US Services Inc.$7K
- Neurocrine Biosciences, Inc.$4K
- Alnylam Pharmaceuticals Inc.$3K
- plus $8K from 9 others
Across 97 payments — averaging $19,710 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.2M
- Roche TCRC, Inc.$633K
- AbbVie$64K
- UCB SA$41K
- F. Hoffmann-la Roche AG$6K
- Neurocrine Biosciences, Inc.$2K
What the payments were for
- Consulting fees$36,99777%
- Speaking & faculty fees$1,9654%
- Travel & lodging$7,66516%
- Food & beverage$1,1662%
- Education$2230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $9,744 |
| Teva Pharmaceuticals USA, Inc. | 9 | $8,596 |
| F. Hoffmann-la Roche AG | 8 | $6,936 |
| Sanofi US Services Inc. | 1 | $6,590 |
| Neurocrine Biosciences, Inc. | 6 | $4,489 |
| Alnylam Pharmaceuticals Inc. | 8 | $3,357 |
| Genentech, Inc. | 2 | $2,740 |
| Acadia Pharmaceuticals Inc | 1 | $1,800 |
| Sage Therapeutics, LLC | 1 | $1,365 |
| UCB, Inc. | 9 | $1,305 |
| Ipsen Biopharmaceuticals, Inc | 1 | $900 |
| Genentech USA, Inc. | 1 | $91 |
| AbbVie | 2 | $54 |
| Merz North America, Inc. | 1 | $27 |
| NS Pharma, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$5,344
- Austedo XR$2,948
- NUPLAZID$1,800
- Non-Covered Product$1,370
- DYSPORT$900
How this compares
$48,015 in reported general payments places this provider in the 90th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 90 | $1,018,344 |
| IngrezzaValbenazine Tosylate | 86 | $915,470 |
| Austedo XrDeutetrabenazine | 33 | $208,601 |
| RytaryCarbidopa/Levodopa | 69 | $132,298 |
| NuplazidPimavanserin Tartrate | 16 | $91,684 |
| NeuproRotigotine | 27 | $30,701 |
| Rasagiline Mesylate | 88 | $22,554 |
| Entacapone | 60 | $17,950 |
| OngentysOpicapone | 16 | $16,363 |
| Rivastigmine | 35 | $13,187 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 39 | $12,881 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 245 | $9,632 |
| Tetrabenazine | 12 | $9,419 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 153 | $7,097 |
| AmantadineAmantadine Hcl | 58 | $4,779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $8,596 | $1,226,945123 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $4,489 | $931,833102 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,800 | $91,68416 claims |
| UCB, Inc.Neupro | $1,305 | $30,70127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 761 neurology providers in Massachusetts.
Other neurology in Boston
- Christopher WrightBoston$2.5M
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Pushpa NarayanaswamiBoston$420K
- Roy FreemanBoston$390K
- Michael LevyBoston$387K
- Leeann BurtonBoston$325K
- Ilena GeorgeBoston$316K
- Andrew BudsonBoston$304K
- Denis BalabanBoston$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.